TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Australian Clinical Labs Ltd ( (AU:ACL) ) has shared an update.
Australian Clinical Labs Ltd has announced an update on its ongoing share buy-back program, revealing that a total of 289,740 ordinary fully paid securities were bought back on the previous day, bringing the total number of securities bought back to 1,492,744. This buy-back initiative is part of the company’s strategy to enhance shareholder value and optimize its capital structure, potentially impacting its market positioning and investor relations positively.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Ltd operates in the healthcare industry, providing pathology services across Australia. The company focuses on delivering high-quality diagnostic services to both healthcare professionals and patients.
Average Trading Volume: 783,599
Technical Sentiment Signal: Buy
Current Market Cap: A$563.7M
For detailed information about ACL stock, go to TipRanks’ Stock Analysis page.